CRISPR Cat Featured in The CRISPR Journal

InBio’s CRISPR Cat project is featured in the upcoming April 2022 edition of The CRISPR Journal, detailing the evolutionary biology and gene editing of cat allergen, Fel d 1. The data of the project indicates that Fel d 1 is both a rational and viable candidate for gene deletion, which may profoundly benefit cat allergy sufferers by removing the major allergen at the source.

Dr. Nicole Brackett, InBio Senior Scientist and project lead, states that “Our approach of targeting the allergen with CRISPR technology would be the first treatment option to effectively remove the major cat allergen from the source, which will be a significant advance compared to existing treatment options.

The feature in the journal has generated a significant amount of international interest, as seen below from the journal’s metrics. Find the latest news stories and coverage on CRISPR cat here. Also, check out our review on ‘Precise editing of allergen genes using CRISPR’ in Frontiers in Allergy.

Dr. Brackett’s cat, Taco, featured on the cover of The CRISPR Journal

InBio 2022 AAAAI Wrap-Up

InBio kicked-off the year by attending our first big conference, the American Academy of Allergy, Asthma and Immunology Annual Meeting, in late February in sunny Phoenix, Arizona. The AAAAI Annual Meeting is always one of the highlights of the year.

InBio was honored that Dr. Anna Pomés was the recipient of the Harold S. Nelson MD, FAAAI Lectureship: Investing Together in Our Future. Congratulations to Anna on this outstanding achievement, which is thoroughly deserved and represents peer recognition of Anna’s research over the past 15 years at the highest level.

It was great to safely meet with colleagues and clients in person. Lots of exciting developments in the field of allergy and asthma! We look forward to our future meetings, including the upcoming WAO/BSACI meeting (25th-27th April, 2022, Edinburgh, UK, Stand C6) and EAACI Congress (1st-3rd July, 2022, Prague, Czech Republic, Booth 28).

Purified Allergen Portfolio

InBio’s purified allergens are manufactured under an ISO 9001:2015 certified Quality Management System and validated using Mass Spectrometry, ELISA, and IgE antibody binding. Purified allergens have many applications, including molecular allergy diagnostics, allergen research, and as allergen standards. Click below for more details on InBio’s full portfolio of over 100 purified allergens as well as the 2022 allergen pipeline, or feel free to visit our website or contact us.

Support for Ukraine

InBio condemns Vladimir Putin’s war on Ukraine and the war crimes being inflicted upon civilians in Ukraine. As a result of a recent fundraiser InBio employees, friends and family have donated $10,000 to support World Central Kitchen in their heroic efforts to provide food and sustenance to Ukrainian civilians and refugees. WCK #ChefsForUkraine is providing 300,000 meals per day. Here’s the latest from Chef José Andres.

Let’s Work Together

Whether you conduct primary research on allergens, develop diagnostic systems, or create products to alleviate environmental and food allergies, you need expertise in action. And that’s exactly what InBio delivers, across everything from highly purified allergens and advanced test kits, to environmental and food allergen testing, to contract research for specialized needs.

  • Broad product catalog
  • Deep scientific background
  • Ongoing commitment to R&D
  • Well-documented subject-matter expertise
  • Direct contact with our scientific team
  • Flexible, collaborative relationships

Want in? Subscribe to the InBio Newsletter stay up to date on all the latest innovations.